A61K 31/529
Forming part of bridged ring systems
Official title: forming part of bridged ring systems
A61K31/529 (Forming part of bridged ring systems) appears on 89 US grants and 195 published applications in this corpus.
Search patents in A61K- Granted patents
- 89
- Published applications
- 195
- Assignees
- 108
- Inventors
- 549
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 1 |
| 2003 | 2 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 4 |
| 2006 | 2 | 2 |
| 2007 | 0 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 1 |
| 2010 | 1 | 4 |
| 2011 | 0 | 5 |
| 2012 | 3 | 4 |
| 2013 | 5 | 2 |
| 2014 | 4 | 11 |
| 2015 | 7 | 13 |
| 2016 | 2 | 12 |
| 2017 | 12 | 11 |
| 2018 | 9 | 11 |
| 2019 | 4 | 8 |
| 2020 | 7 | 9 |
| 2021 | 4 | 10 |
| 2022 | 4 | 8 |
| 2023 | 5 | 15 |
| 2024 | 4 | 17 |
| 2025 | 3 | 21 |
| 2026 | 6 | 22 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Macrocyclic glucagon-like peptide 1 receptor agonists15 Sep 2026US 12,735,433 B2Eli Lilly and Company
- Method for efficiently extracting and separating high-purity tetrodotoxin from pufferfish viscera18 Aug 2026US 12,709,618 B2Zhongyang Biotechnology (Shanghai) Co., LTD.
- Antimalarial agents19 May 2026US 12,629,374 B2Merck Sharp & Dohme Corp.
- Methods for treating nail brittleness, fragility, or pitting28 Apr 2026US 12,611,408 B2Chemistry RX
- Macrocyclic ULK1/2 inhibitors7 Apr 2026US 12,594,277 B2Sanford Burnham Prebys Medical Discovery Institute
- Cell proliferation modulators and uses thereof1 Oct 2026US 2026/0294925 A1Kumquat Biosciences Inc.
- Macrocyclic EGFR Inhibitor, and Preparation Method Therefor and Pharmaceutical Use Thereof24 Sep 2026US 2026/0285877 A1Abbisko Therapeutics Co., Ltd.
- Uses of JAK Inhibitors in the Management of Sepsis and Comorbidities17 Sep 2026US 2026/0272935 A1Emory University
- Deuterated compounds30 Jul 2026US 2026/0217685 A1Sun Pharmaceutical Industries Limited
- Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor16 Jul 2026US 2026/0199347 A1Acerta Pharma B.V.
Most cited
By later US patents
- Organic compounds93US 8,536,159 B2Intra-Cellular Therapies, Inc. · 2013
- Method of anesthesia84US 6,030,974 AThe Regents of the University of California · 2000
- Methods for enhancing wound healing79US 6,447,787 B1Mayo Foundation for Medical Education and Research · 2002
- Use of neurotoxin therapy for treatment of urologic and related disorders67US 6,365,164 B1University Technology Corporation · 2002
- Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections49US 9,216,996 B2Gilead Sciences, Inc. · 2015